Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 02.05.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
02.05.23Notice - Termination of coverage - Termination of coverage203Edison Investment Research is terminating coverage on Centaur Media (CAU), Rank Group (RNK), HBM Healthcare Investment (HBMN), European Assets Trust (EAT) and Fidelity Emerging Markets Limited (FEML)....
► Artikel lesen
02.05.23Agnico Eagle Mines - A year of optimisation ahead620Agnico Eagle Mines (AEM) started the year with strong quarterly production of 813koz at an US$832/oz total cash cost and a US$1,125/oz all-in sustaining cost (AISC). A number of records were achieved...
► Artikel lesen
02.05.23Molten Ventures - Initial signs of stabilisation in H223496Molten Ventures released its FY23 trading update (to end-March 2023), with its NAV per share down c 17% in FY23 to c 775p. That said, it posted only a minor 2% decline in its gross portfolio fair value...
► Artikel lesen
02.05.23Pixium Vision - Focusing on reaching the PRIMAvera milestone445Having completed the required 38 implantations in late 2022, Pixium Vision's key upcoming clinical milestone is the primary efficacy data, expected in or around year-end 2023, from the PRIMAvera European...
► Artikel lesen
02.05.23Creo Medical - Entering phase of accelerating growth inflection312FY22 was a key inflection period for Creo with significant traction in the adoption of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform, reflected...
► Artikel lesen
02.05.23AFT Pharmaceuticals - Maxigesic IV closer to FDA approval164AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form of its flagship pain relief medicine. The PDUFA date...
► Artikel lesen
02.05.23Carr's Group - Weather affects H123 performance287As flagged in its February update, the Speciality Agriculture division of Carr's Group experienced a weaker trading environment from November onwards, while trading in the Engineering division was initially...
► Artikel lesen
02.05.23Paradigm Biopharma - Active pipeline and catalysts ahead241Paradigm has shared its March 2023 quarterly update. In Q323, net cash outflow from operating activities was A$10.3m (A$28.1m for the first nine months of FY23). R&D costs amounted to A$9.0m, attributed...
► Artikel lesen
02.05.23Actinogen Medical - Continued focus on Xanamem342Actinogen's Q323 update reiterated the company's focus on advancing its lead asset Xanamem. Patient recruitment in the Phase IIa XanaCIDD study in cognitive impairment (CI) associated with major depressive...
► Artikel lesen
02.05.23Sequana Medical - New funding to support clinical progression438Sequana Medical has raised €15.8m through a private placement of new shares and subscription rights. Roughly 4.445m new shares were issued at €3.55/share, increasing the number of shares outstanding...
► Artikel lesen
02.05.23Dowlais Group - A premium automotive business535The listing of Dowlais in April 2023 launched the GKN group of automotive components businesses, market-leading automotive driveline and powder metallurgy manufactured components, as a standalone entity....
► Artikel lesen
02.05.231Spatial - New SaaS apps to drive high-margin growth3991Spatial's full year results confirm the solid progress made over the course of the year with revenue growing 11%, recurring revenues growing 21% and EBITDA margins expanding from 15.5% to 16.7%. With...
► Artikel lesen